Quartet Medicine snags $6.25 mln Series A
Cambridge, Massachusetts-based Quartet Medicine, a biotech company focused on treating chronic pain and inflammation, has raised $6.25 million in funding, bringing its total Series A tally to $23.25 million. The investors in this round included Remeditex Ventures LLC. In conjunction with the funding, Remeditex CEO John Creecy has been added to Quartet Medicine's board of directors.
8 October 2015•5 mins read
